Cargando…
Pembrolizumab-Induced Adrenal Insufficiency in Patients with Untreated Advanced Non-Small Cell Lung Cancer: A Case Series
Pembrolizumab-induced adrenal insufficiency (AI) is recognized as a rare immune-related adverse event (irAE) that can be fatal if diagnosis is delayed. Clinical features of AI in patients with advanced non-small cell lung cancer (NSCLC) who received pembrolizumab as the first-line treatment were obs...
Autores principales: | Sonehara, Kei, Tateishi, Kazunari, Araki, Taisuke, Komatsu, Masamichi, Akahane, Jumpei, Yamamoto, Hiroshi, Hanaoka, Masayuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647110/ https://www.ncbi.nlm.nih.gov/pubmed/34949996 http://dx.doi.org/10.1159/000519597 |
Ejemplares similares
-
Predictive Factors Correlated with the Development of Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors
por: Sonehara, Kei, et al.
Publicado: (2022) -
A Case of Lung Adenocarcinoma with Long-Term Response after Late-Onset Pembrolizumab-Induced Acute Adrenal Insufficiency
por: Sonehara, Kei, et al.
Publicado: (2021) -
Prognostic value of the geriatric nutritional risk index among patients with previously treated advanced non‐small cell lung cancer who subsequently underwent immunotherapy
por: Sonehara, Kei, et al.
Publicado: (2021) -
Lung immune prognostic index as a prognostic factor in patients with small cell lung cancer
por: Sonehara, Kei, et al.
Publicado: (2020) -
Association of lung immune prognostic index with survival outcome in advanced thymic carcinoma patients treated with palliative intent chemotherapy
por: Araki, Taisuke, et al.
Publicado: (2022)